Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120393
Status:
COMPLETED
Last Update Posted:
2010-02-05
First Post:
2005-07-12
Brief Title:
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to AtazanavirRitonavir
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase IIIB Open-label Randomized Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATVr in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPVr Based Regimen
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with HIV who are virologically suppressed on a lopinavirritonavir combination highly active antiretroviral therapy HAART regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavirritonavir or change to atazanavirritonavir in combination with current nucleoside reverse transcriptase inhibitors NRTIs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None